Fig. 4From: Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implicationsSpecific concentration (as a percentage of injected activity) for lesions (for each site of disease) and the main organs at risk 1, 4 and 24Â h after administrationBack to article page